Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionFixed dose combination of Mosapride / Bacillus subtilis / Streptococcas feacium
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase II
Standard IndicationIrritable bowel syndrome
Indication DetailsTreat irritable bowel syndrome
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today